The fist distribution agreements in Germany and Belgium for the Stentys drug-eluting stent for treating below-the-knee arteries have been announced by the company. This makes the product the first drug-eluting stent commercialised for this indication in Europe.
The Stentys stent obtained CE marking for the below-the-knee indication at the end of 2015 following the excellent results achieved by the PES BTK-70 study, where it prevented amputation in 99% of the 70 patients treated for critical limb ischaemia. The rapid launch of its commercialisation reflects a major medical need, particularly in Germany, Europe’s largest market, according to a company release.
Gonzague Issenmann, chief executive officer and co-founder of Stentys, comments: “We are delighted by the interest we received for our stent.”